MDxHealth SA ADR
$ 0.41
1.87%
30 Jul - close price
- Market Cap 21,110,800 USD
- Current Price $ 0.41
- High / Low $ 0.42 / 0.40
- Stock P/E N/A
- Book Value -0.39
- EPS -0.65
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -24.40 %
- 52 Week High 5.33
- 52 Week Low 0.40
About
MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, exemplifies the company's commitment to clinical efficacy and personalized medicine, establishing a strong foothold in a rapidly growing market. As the demand for targeted cancer therapies increases, MDxHealth is poised to expand its diagnostic offerings, effectively addressing critical unmet needs in oncology and improving patient outcomes. With its innovative solutions and strategic growth initiatives, MDxHealth is well-positioned to play a vital role in the future of cancer diagnostics.
Analyst Target Price
$2.80
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-26 | 2025-11-12 | 2025-08-14 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-07 | 2023-08-23 |
| Reported EPS | -0.17 | -0.17 | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.31 | -0.31 | -0.39 | -0.4 | -0.3 |
| Estimated EPS | -0.15 | -0.13 | -0.11 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.25 | -0.19 | -0.22 |
| Surprise | -0.02 | -0.04 | -0.05 | -0.02 | -0.06 | 0.05 | -0.15 | -0.05 | -0.01 | -0.14 | -0.21 | -0.08 |
| Surprise Percentage | -13.3333% | -30.7692% | -45.4545% | -16.6667% | -46.1538% | 26.3158% | -60% | -19.2308% | -3.3333% | -56% | -110.5263% | -36.3636% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2026-07-30 05:41:35
This article provides a technical analysis of MDxHealth SA (MDXH), covering its stock price, support and resistance levels, and various technical indicators and moving averages. As of July 29, 2026, MDXH has a price momentum score of 4.52 and is trading between a resistance level of $0.49 and a support level of $0.35, suggesting suitability for range-bound swing trading. While individual indicators show mixed signals, the overall technical rating based on moving averages and other technical indicators is Neutral.
2026-07-25 10:40:59
This article provides a financial health analysis of MDxHealth SA (MDXH), noting its current financial score of 7.19, which ranks it 139 out of 386 in the Biotechnology & Medical Research industry. The company is described as stable with high operating efficiency, reporting a 12.74% year-over-year revenue increase and a 3.71% net profit increase in its latest quarter. The report also highlights specific financial dimensions like quality of earnings, operational efficiency, growth potential, and shareholder returns, while noting that relevant data for some metrics have not been disclosed.
2026-07-24 21:13:00
Mdxhealth (NASDAQ: MDXH) has received a warning from Nasdaq for failing to meet the minimum Market Value of Listed Securities requirement of US$35 million. The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a market value of at least US$35 million for 10 consecutive business days. This notification follows an earlier warning regarding non-compliance with Nasdaq's minimum bid price requirement, and failure to meet the new requirement could lead to delisting and adversely affect the company's ability to raise capital.
2026-07-24 21:13:00
Mdxhealth SA has received a Nasdaq notification for non-compliance with the minimum market value requirement, following an earlier notice regarding its failure to meet the minimum bid price. The company now has 180 days, until January 19, 2027, to regain compliance by maintaining a market value above $35 million for ten consecutive business days. Mdxhealth stated its business operations are not affected and it intends to address the deficiency to avoid potential delisting.
2026-07-24 20:13:00
This article provides a revenue breakdown for MDxHealth SA (MDXH), detailing its regional revenue contribution for FY2023. The United States of America accounts for the vast majority of revenue at 99.31%, with Europe contributing 0.68% and the rest of the world 0.01%. Information regarding revenue by business segment was not disclosed by the company for 2023.
2026-07-24 20:13:00
The article provides information on MDxHealth SA (MDXH) stock, including its current trading price, market capitalization, and dividend history. It states that the company has not distributed any dividends over the past five years. The page outlines various financial and company profile sections available on the TradingKey platform.
